Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome

Movement Disorders

Volumn 26, Issue 11, 2011, Pages 2065-2072

  Winkelman, John W ^a   Bogan, Richard K ^b   Schmidt, Markus H ^b   Hudson, John D ^b   Derossett, Sarah E ^c   Hill Zabala, Christina E ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SleepMed ^*  (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Gabapentin enacarbil; Polysomnography; Restless legs syndrome; Sleep disturbance

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; GABAPENTIN ENACARBIL; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AROUSAL; ARTICLE; BODY MASS; CELLULITIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL RESTLESS LEG SCALE; LIMB MOVEMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; RESTLESS LEGS SYNDROME; SCORING SYSTEM; SLEEP AROUSAL DISORDER; SLEEP DISORDER; SLEEP QUALITY; SOMNOLENCE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

EID: 84940615775     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23771     Document Type: Article

References (38)

1. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-119.
2. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286-1292.
3. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5: 237-246.
4. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997; 12: 61-65.
5. Hornyak M, Kopasz M, Berger M, Riemann D, Voderholzer U. Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. J Clin Psychiatry 2005; 66: 1139-1145.
6. Walters AS, Rye DB. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 2009; 32: 589-597.
7. Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006; 7: 545-552.
8. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004; 27: 907-914.
9. Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 2003; 48: 82-86.
10. Jama L, Hirvonen K, Partinen M, et al. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance. Sleep Med 2009; 10: 630-636.
11. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study-the PRELUDE study. Sleep Med 2006; 7: 407-417.
12. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008; 23: 2267-2302.
13. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59: 1573-1579.
14. Cundy KC, Annamalai T, Bu L, et al. XP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004; 311: 324-333.
15. Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004; 311: 315-323.
16. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008; 48: 1378-1388.
17. Lal R, Sukbuntherng J, Luo W, et al. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled, crossover study in healthy volunteers. Clin Ther 2009; 31: 1776-1786.
18. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW, the XP, 052 Study Group. Randomized, double-blind, placebo-controlled trial of XP13512/GSK1838262 in patients with RLS. Neurology 2009; 72: 439-446.
19. Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009; 32: 159-168.
20. Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: A phase 2b, two-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009; 32: 311-320.
21. Iber C, Ancoli-Israel S, Chesson A, Quan SF. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. Westchester, IL: American Academy of Sleep Medicine; 2007.
22. Atlas Task Force of The American Sleep Disorders Association. Recording and scoring leg movements. Sleep 1993; 16: 748-759.
23. Coleman RM. Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome. In: Guilleminault C, ed. Sleeping and Waking Disorders: Indications and Techniques. Menlo Park, NJ: Addison-Wesley; 1982: 265-295.
24. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington, DC: US Government Printing Office, US Public Health Service; 1968.
25. Zucconi M, Ferri R, Allen R, et al. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med 2006; 7: 175-183.
26. Hening WA, Allen RP. Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures. Sleep Med 2003; 4: 95-97.
27. Lahmeyer H, Wilcox CS, Kann J, Leppik I. Subjective efficacy of zolpidem in outpatients with chronic insomnia. A double-blind comparison with placebo. Clin Drug Investig 1997; 13: 134-144.
28. National Institute of Mental Health (NIMH). Early Clinical Drug Evaluation Unit (ECDEU). Clinical Global Impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: NIMH; 1976: 218-222.
29. Calloway MO, Bharmal A, Hill-Zabala CE, Allen RP. Development and validation of a Subjective Post Sleep Diary (SPSD) to assess sleep status in subjects with restless legs syndrome. Sleep Med 2011; in press.
30. Reitan, R. Validity of the trail-making test as an indicator of organic brain disease. Percept Mot Skills 1958; 8: 271-276.
31. Goodglass H, Kaplan E. Assessment of Aphasia and Related Disorders. Philadelphia: Lea & Febiger; 1972.
32. Rosen WG. Verbal fluency in aging and dementia. J Clin Neuropsychol 1980; 2: 135-146.
33. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999; 52: 938-943.
34. Saletu B, Gruber G, Saletu M, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000; 41: 181-189.
35. Saletu M, Anderer P, Saletu B, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 2000; 41: 190-199.
36. Saletu M, Anderer P, Saletu-Zyhlarz GM, et al. Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. J Neural Transm 2010; 117: 463-473.
37. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006; 81: 17-27.
38. Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trial. Sleep Med 2008; 9: 874-881.